Email ID
Password
Scrip   
Daiichi Sankyo's edoxaban enters pivotal trial for VTE
04 February 2010
Ian Haydock

Daiichi Sankyo has begun recruiting for a key Phase III multinational clinical trial programme for its oral direct Factor Xa inhibitor, edoxaban.

The pivotal HOKUSAI VTE study will compare the anticoagulant with standard of care warfarin in the prevention of recurrent venous thromboembolic...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36